Cytochrome P450 1B1 Contributes to the Development of Atherosclerosis and Hypertension in Apolipoprotein E-Deficient Mice

Hypertension

Volumn 67, Issue 1, 2016, Pages 206-213

  Song, Chi Young ^a   Ghafoor, Khuzema ^a   Ghafoor, Hafiz U ^a   Khan, Nayaab S ^a   Thirunavukkarasu, Shyamala ^a   Jennings, Brett L ^a   Estes, Anne M ^a   Zaidi, Sahar ^a   Bridges, Dave ^a   Tso, Patrick ^b   Gonzalez, Frank J ^c   Malik, Kafait U ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

apolipoprotein E, deficiency; cytochrome P450 1B1; diet, atherogenic; plasma lipids; vascular, remodeling

Indexed keywords

2,3',4,5' TETRAMETHOXYSTILBENE; APOLIPOPROTEIN E; COLLAGEN; CYTOCHROME P450 1B1; DIMETHYL SULFOXIDE; ELASTIN; LIPID; REACTIVE OXYGEN METABOLITE; STILBENE DERIVATIVE; UNCLASSIFIED DRUG; RNA;

ANIMAL CELL; ANIMAL EUTHANASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; ATHEROGENIC DIET; ATHEROSCLEROSIS; BLOOD PRESSURE; BLOOD SAMPLING; BLOOD VESSEL INJURY; CELL INFILTRATION; CONTROLLED STUDY; HISTOPATHOLOGY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; LIPID ABSORPTION; LIPID ANALYSIS; LIPID BLOOD LEVEL; MACROPHAGE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; T LYMPHOCYTE; TAIL; ANIMAL; BIOSYNTHESIS; DEFICIENCY; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PRESSURE; CYTOCHROME P-450 CYP1B1; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HYPERTENSION; MALE; MICE; MICE, KNOCKOUT; RNA; VASODILATION;

EID: 84951570156     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.06427     Document Type: Article

References (46)

1. Sutter TR, Tang YM, Hayes CL, Wo YY, Jabs EW, Li X, Yin H, Cody CW, Greenlee WF. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J Biol Chem. 1994;269:13092-13099.
2. Korashy HM, El-Kadi AO. The role of aryl hydrocarbon receptor in the pathogenesis of cardiovascular diseases. Drug Metab Rev. 2006;38:411-450. doi: 10.1080/03602530600632063.
3. Zhao W, Parrish AR, Ramos KS. Constitutive and inducible expression of cytochrome P450IA1 and P450IB1 in human vascular endothelial and smooth muscle cells. In Vitro Cell Dev Biol Anim. 1998;34:671-673. doi: 10.1007/s11626-998-0060-7.
4. Conway DE, Sakurai Y, Weiss D, Vega JD, Taylor WR, Jo H, Eskin SG, Marcus CB, McIntire LV. Expression of CYP1A1 and CYP1B1 in human endothelial cells: regulation by fluid shear stress. Cardiovasc Res. 2009;81:669-677. doi: 10.1093/cvr/cvn360.
5. Tang Y, Scheef EA, Wang S, Sorenson CM, Marcus CB, Jefcoate CR, Sheibani N. CYP1B1 expression promotes the proangiogenic phenotype of endothelium through decreased intracellular oxidative stress and thrombospondin-2 expression. Blood. 2009;113:744-754. doi: 10.1182/blood-2008-03-145219.
6. Choudhary D, Jansson I, Stoilov I, Sarfarazi M, Schenkman JB. Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004;32:840-847.
7. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR. 17 betaestradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci U S A. 1996;93:9776-9781.
8. Sissung TM, Price DK, Sparreboom A, Figg WD. Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormonemediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res. 2006;4:135-150. doi: 10.1158/1541-7786. MCR-05-0101.
9. Paigen B, Holmes PA, Morrow A, Mitchell D. Effect of 3-methylcholanthrene on atherosclerosis in two congenic strains of mice with different susceptibilities to methylcholanthrene-induced tumors. Cancer Res. 1986;46:3321-3324.
10. Moorthy B, Miller KP, Jiang W, Ramos KS. The atherogen 3-methylcholanthrene induces multiple DNA adducts in mouse aortic smooth muscle cells: role of cytochrome P4501B1. Cardiovasc Res. 2002;53:1002-1009.
11. Jennings BL, Sahan-Firat S, Estes AM, Das K, Farjana N, Fang XR, Gonzalez FJ, Malik KU. Cytochrome P450 1B1 contributes to angiotensin II-induced hypertension and associated pathophysiology. Hypertension. 2010;56:667-674. doi: 10.1161/HYPERTENSIONAHA.110.154518.
12. Jennings BL, Estes AM, Anderson LJ, Fang XR, Yaghini FA, Fan Z, Gonzalez FJ, Campbell WB, Malik KU. Cytochrome P450 1B1 gene disruption minimizes deoxycorticosterone acetate-salt-induced hypertension and associated cardiac dysfunction and renal damage in mice. Hypertension. 2012;60:1510-1516. doi: 10.1161/HYPERTENSIONAHA.112.202606.
13. Sahan-Firat S, Jennings BL, Yaghini FA, Song CY, Estes AM, Fang XR, Farjana N, Khan AI, Malik KU. 2,3′,4,5′-Tetramethoxystilbene prevents deoxycorticosterone-salt-induced hypertension: contribution of cytochrome P-450 1B1. Am J Physiol Heart Circ Physiol. 2010;299:H1891-H1901. doi: 10.1152/ajpheart.00655.2010.
14. Jennings BL, Montanez DE, May ME Jr, Estes AM, Fang XR, Yaghini FA, Kanu A, Malik KU. Cytochrome P450 1B1 contributes to increased blood pressure and cardiovascular and renal dysfunction in spontaneously hypertensive rats. Cardiovasc Drugs Ther. 2014;28:145-161. doi: 10.1007/s10557-014-6510-4.
15. Yaghini FA, Song CY, Lavrentyev EN, Ghafoor HU, Fang XR, Estes AM, Campbell WB, Malik KU. Angiotensin II-induced vascular smooth muscle cell migration and growth are mediated by cytochrome P450 1B1-dependent superoxide generation. Hypertension. 2010;55:1461-1467. doi: 10.1161/HYPERTENSIONAHA.110.150029.
16. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol. 2005;25:29-38. doi: 10.1161/01. ATV.0000150649.39934.13.
17. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241. doi: 10.1038/35025203.
18. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045-2051.
19. Chun YJ, Kim S, Kim D, Lee SK, Guengerich FP. A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res. 2001;61:8164-8170.
20. Johnston TP. The P-407-induced murine model of dose-controlled hyperlipidemia and atherosclerosis: a review of findings to date. J Cardiovasc Pharmacol. 2004;43:595-606.
21. Rikhter MD. Collagen synthesis in atherosclerosis: too much and not enough. Cardiovas Res.1999;41:376-384.
22. Maurice P, Blaise S, Gayral S, Debelle L, Laffargue M, Hornebeck W, Duca L. Elastin fragmentation and atherosclerosis progression: the elastokine concept. Trends Cardiovasc Med. 2013;23:211-221. doi: 10.1016/j.tcm.2012.12.004.
23. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84:1381-1478. doi: 10.1152/physrev.00047.2003.
24. -/- mice. Am J Physiol Heart Circ Physiol. 2010;298:H24-H32. doi: 10.1152/ajpheart.00799.2009.
25. Cyrus T, Witztum JL, Rader DJ, Tangirala R, Fazio S, Linton MF, Funk CD. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest. 1999;103:1597-1604. doi: 10.1172/JCI5897.
26. Liu C, Desikan R, Ying Z, Gushchina L, Kampfrath T, Deiuliis J, Wang A, Xu X, Zhong J, Rao X, Sun Q, Maiseyeu A, Parthasarathy S, Rajaqopalan S. Effects of a novel pharmacologic inhibitor of myeloperoxidase in a mouse atherosclerosis model. PLoS ONE. 2012;7:e50767. doi:10.1371/journal.pone.0050767.
27. Nomura J, Busso N, Ives A, Matsui C, Tsujimoto S, Shirakura T, Tamura M, Kobayashi T, So A, Yamanaka Y. Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice. Sci Rep. 2014;4:4554. doi: 10.1038/srep04554.
28. Naruse K, Shimizu K, Muramatsu M, Toki Y, Miyazaki Y, Okumura K, Hashimoto H, Ito T. Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta. PGH2 does not contribute to impaired endothelium-dependent relaxation. Arterioscler Thromb. 1994;14:746-752.
29. Inoue T, Node K. Vascular failure: A new clinical entity for vascular disease. J Hypertens. 2006;24:2121-2130. doi: 10.1097/01. hjh.0000249684.76296.4f.
30. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014;20:1126-1167. doi: 10.1089/ars.2012.5149.
31. Kerzee JK, Ramos KS. Constitutive and inducible expression of Cyp1a1 and Cyp1b1 in vascular smooth muscle cells: role of the Ahr bHLH/PAS transcription factor. Circ Res. 2001;89:573-582.
32. Ward JM, Nikolov NP, Tschetter JR, Kopp JB, Gonzalez FJ, Kimura S, Siegel RM. Progressive glomerulonephritis and histiocytic sarcoma associated with macrophage functional defects in CYP1B1-deficient mice. Toxicol Pathol. 2004;32:710-718.
33. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP, Sutter TR. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res. 1996;56:2979-2984.
34. Kirabo A, Fontana V, de Faria AP, et al. DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest. 2014;124:4642-4656. doi: 10.1172/JCI74084.
35. Waddington EI, Croft KD, Sienuarine K, Latham B, Puddey IB. Fatty acid oxidation products in human atherosclerotic plaque: an analysis of clinical and histopathological correlates. Atherosclerosis. 2003;167:111-120.
36. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000;105:1605-1612. doi: 10.1172/JCI7818.
37. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1990;15:327-331.
38. Keidar S, Attias J, Smith J, Breslow JL, Hayek T. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun. 1997;236:622-625. doi: 10.1006/bbrc.1997.6844.
39. Chen J, Kuhlencordt PJ, Astern J, Gyurko R, Huang PL. Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice. Circulation. 2001;104:2391-2394.
40. Ueda H, Yagi S, Kaneko Y. Hydralazine and plasma renin activity. Arch Intern Med. 1968;122:387-391.
41. Larsen MC, Bushkofsky JR, Gorman T, Adhami V, Mukhtar H, Wang S, Reeder SB, Sheibani N, Jefcoate CR. Cytochrome P450 1B1: An unexpected modulator of liver fatty acid homeostasis. Arch Biochem Biophys. 2015;571:21-39. doi: 10.1016/j.abb.2015.02.010.
42. Belton OA, Duffy A, Toomey S, Fitzgerald DJ. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation. 2003;108:3017-3023. doi: 10.1161/01.CIR.0000104565.78013.AD.
43. Kirby NS, Lundber MH, Wright WR, Warner TD, Paul-Clark MJ, Mitchell JA. COX-2 protects against atherosclerosis independently of local vascular prostacyclin: Identification of COX-2 associated pathways implicate RgI 1 and lymphocyte networks. PLoS One. 2014;9:1-12. e98165.
44. Frank PG, Lee H, Park DS, Tandon NN, Scherer PE, Lisanti MP. Genetic ablation of caveolin-1 confers protection against atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:98-105. doi: 10.1161/01. ATV.0000101182.89118.E5.
45. Fernández-Hernando C, Yu J, Suárez Y, Rahner C, Dávalos A, Lasunción MA, Sessa WC. Genetic evidence supporting a critical role of endothelial caveolin-1 during the progression of atherosclerosis. Cell Metab. 2009;10:48-54. doi: 10.1016/j.cmet.2009.06.003.
46. Vasiliou V, Gonzalez FJ. Role of CYP1B1 in glaucoma. Annu Rev Pharmacol Toxicol. 2008;48:333-358. doi: 10.1146/annurev. pharmtox.48.061807.154729.